Make confident treatment decisions with clear and easy to explain results!

Professor Michael Untch, Head of Clinic for Gynecology, Gynecologic Oncology and Obstetrics from HELIOS Clinic Berlin-Buch in Berlin, Germany presented a case study on chemotherapy decision using the EndoPredict® Breast Cancer Prognostic Test.

The case study includes a comprehensive report on the patient's individualized risk score, which helped the patient and her clinician decide on the most appropriate treatment with minimum potential side effects.

Snapshot of Patient Case Study:

50 years old, postmenopausal, pT2, N1, G2, L0, V0, R0, ER 30/80%, PR 100/90%, Ki67 10%, lobular early-stage breast cancer patient

Poll of other clinicians’ case opinions

How her EndoPredict® result changed the treatment decision

Clinical validation of the test in this patient group

The patient’s individualized risk score:

Based on the above risk score, the patient and her clinician decided to proceed without chemotherapy, allowing her to avoid the potential side effects.

Click here for the patient case study’s full report and Prof. Untch’s video explanation of the case study